Table 2.
Toxicities observed in >15% of patients, by schedule
| Toxicity | Q1Wk (n = 12) | Q2Wk (n = 15) | Q3Wk (n = 18) | Q6Wk (n = 17) | All schedules (n = 62) |
|---|---|---|---|---|---|
| Peripheral neuropathy* | 5 (42%) | 10 (67%) | 13 (72%) | 16 (94%) | 44 (71%) |
| NOS | |||||
| Nausea | 4 (33%) | 10 (67%) | 12 (67%) | 12 (71%) | 38 (61%) |
| Fatigue | 6 (50%) | 6 (40%) | 16 (89%) | 9 (53%) | 37 (60%) |
| Anorexia | 4 (33%) | 6 (40%) | 9 (50%) | 5 (29%) | 24 (39%) |
| Diarrhea | 6 (50%) | 4 (27%) | 6 (33%) | 8 (47%) | 24 (39%) |
| Constipation | 4 (33%) | 2 (13%) | 8 (44%) | 7 (41%) | 21 (34%) |
| AST/ALT elevation | 0 | 5 (33%) | 6 (33%) | 1 (6%) | 12 (19%) |
| Pyrexia | 1 (8%) | 2 (13%) | 5 (28%) | 3 (18%) | 11 (18%) |
| Vomiting | 1 (8%) | 4 (27%) | 6 (33%) | 0 | 11 (18%) |
| Rigors | 2 (17%) | 2 (13%) | 4 (22%) | 2 (12%) | 10 (16%) |
| Weight decrease | 0 | 1 (7%) | 3 (17%) | 6 (35%) | 10 (16%) |
| Bone pain | 3 (25%) | 2 (13%) | 1 (6%) | 3 (18%) | 9 (15%) |
| Musculoskeletal pain | 2 (17%) | 1 (7%) | 5 (28%) | 1 (6%) | 9 (15%) |
NOS = not otherwise specified.
*
Any grade